Network Meta-analysis of oral Chinese patent medicine for adjuvant treatment of primary liver cancer.
10.19540/j.cnki.cjcmm.20200721.501
- Author:
Rong-Rong ZHANG
1
;
Ming-Yi SHAO
2
;
Yu FU
2
;
Rui-Xia ZHAO
2
;
Jing-Wen WANG
1
;
Man LI
1
;
Yun-Xia ZHAO
1
;
Fan-Lei SHAO
1
Author Information
1. Henan University of Chinese Medicine Zhengzhou 450046, China.
2. the First Affiliated Hospital of Henan University of Chinese Medicine, Henan Center for Evidence-based Medicine of Traditional Chinese Medicine Zhengzhou 450000, China.
- Publication Type:Meta-Analysis
- Keywords:
network Meta-analysis;
oral Chinese patent medicine;
primary liver cancer;
transcatheter artery chemoembolization
- MeSH:
Carcinoma, Hepatocellular/drug therapy*;
Chemoembolization, Therapeutic;
China;
Drugs, Chinese Herbal;
Humans;
Liver Neoplasms/drug therapy*;
Network Meta-Analysis;
Nonprescription Drugs;
Quality of Life
- From:
China Journal of Chinese Materia Medica
2021;46(9):2333-2343
- CountryChina
- Language:Chinese
-
Abstract:
Network Meta-analysis was used to evaluate the efficacy and safety of different oral Chinese patent medicines combined with transcatheter arterial chemoembolization(TACE) in the treatment of primary liver cancer. Randomized controlled trials of oral Chinese patent medicines for primary liver cancer were retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library and EMbase databases from inception to May 2020. According to the Cochrane recommendation standard, the quality of the included articles was evaluated, and the data were analyzed by RevMan, R software and GeMTC software. A total of 10 kinds of oral Chinese patent medicines and 68 RCTs were included. Network Meta-analysis results showed that: as compared with TACE alone, 10 kinds of oral Chinese patent medicines combined with TACE showed advantages in effective rate, 1-year survival rate, 2-year survival rate, KPS score improvement rate and reduced adverse reaction incidence. In the pairwise comparison of oral Chinese patent medicines, the results showed that Cidan Capsules were superior to Jinlong Capsules and Xihuang Pills in 1-year survival rate. According to the probabi-lity ranking results: Shenyi Capsules and Ganfule were more obvious in improving the effective rate; Cidan Capsules and Shenyi Capsules were more effective in improving the 1-year survival rate; Pingxiao Capsules and Shenyi Capsules had better efficacy in improving 2-year survival rate; Huaier Granules and Shenyi Capsules had better efficacy in improving the quality of life; Huisheng Oral Liquid and Ganfule were more effective in reducing the incidence of adverse reactions(such as nausea, vomiting and leukocytosis). The current evidence showed that oral Chinese patent medicine combined with TACE was superior to TACE alone in efficacy and safety. In terms of the effective rate, 1-year survival rate, 2-year survival rate, KPS score improvement rate and reduced adverse reaction incidence, the optimal treatment measures were Shenyi Capsules, Cidan Capsules, Pingxiao Capsules, Huaier Granules and Huisheng Oral Liquid in turn. However, due to the limitations of the research, the current level of evidence is not high, and clear conclusions and evi-dence strength still need to be further verified and improved by high-quality researches.
